announced Friday an FDA fast track designation for a single-dose Covid and flu vaccine candidate.
The companies earlier began a Phase 1 trial to determine the safety of the candidate in healthy adults.
The candidate provides protection against the BA.4/BA.5 Omicron sublineages and four different influenza strains — as recommended for use in the northern hemisphere by the World Health Organization.
The announcement comes after the FDA Thursday authorized the updated bivalent
and Moderna Covid-19 vaccines for children as young as six months. This age revision lowers
‘s previous authorization for children over four and Moderna’s of six years old and up.
Pfizer stock (ticker: PFE) stayed flat in premarket trading Friday, while
(BNTX) dipped 0.3%. So far this year, Pfizer shares have fallen 12.3%, and BioNTech shares have fallen 33.4%, as of Thursday’s close.
Write to Emily Dattilo at firstname.lastname@example.org